FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034291261> ?p ?o ?g. }

• W2034291261 endingPage "749" @default.
• W2034291261 startingPage "747" @default.
• W2034291261 abstract "To the Editors: The use of human immunodeficiency virus (HIV) genotyping for identifying the most effective regimens in HIV-infected adults failing highly active antiretroviral therapy led to improved virologic response as compared with regimens selected on the basis of antiretroviral exposure history. In contrast, similar studies conducted in small cohorts of HIV-infected children failed to demonstrate a clear advantage of antiretroviral resistance testing over antiretroviral exposure history. In this study, we have genotyped HIV reverse transcription and protease genes in 17 children (ages 4.5–11.3 years) between 2000 and 2001, at treatment failure and have changed antiretroviral drugs according to HIV genotype profiles. All 17 children who were included showed an elevated viral load (>1000 copies/mL) for at least 9 months during the last year before genotyping and had failed from 1–5 regimens during that time. All the HIV-infected children had received a combination of at least 2 nucleoside reverse transcriptase inhibitors (NRTIs) (17 of 17) and while 8 of 17 had been treated with a PI containing regimen; none of them was previously treated with non-NRTIs (Table 1). Adherence to therapy was based on reports from children and caretakers and on calculation of quantities of drugs that were requested at each visit. At the time of treatment failure, we identified substitutions in both the reverse transcription and the protease genes in samples from 94% of children.TABLE 1: Nucleoside Reverse Transcription Inhibitors Used in HIV TreatmentWild-type sequences could not be identified in any sample from this cohort of HIV-infected children. Drug-specific genotypic resistance, identified on the basis of the IAS mutation list,4 was commonly observed for all the NRTIs as shown in detail in Table 1. Antiretroviral therapy was changed by substitution of at least one antiretroviral medication in all patients, except in patient 17. Since none of the patients had been previously exposed to non-NRTI drugs whereas 8 of 17 had received a drug of the protease inhibitor class, we introduced efavirenz in the therapeutic regimens of 11 children. Virologic and immunologic data were collected at 2- to 3-month intervals for at least 12 months. We observed a significant suppression of viral load (<1000 copies) 3-6 months after treatment change. HIV suppression was detected in 8 of the 17 patients from 6 to 35 months (stably undetectable in 5 cases), whereas in another 5 children viral load remained elevated through 12 months of follow-up. CD4+ percentages showed a significant increase from baseline levels in the same children who showed virologic suppression, except in patient 10 who had already started the treatment with 44% of CD4, suggesting that their treatment regimens were effective to induce immunologic reconstitution. The remaining patients (patients 1, 3, 4 and 13) showed a rapid, but transient, decline of viral load after treatment change. Because of the high risk of false negatives, we have performed an additional HIV genotyping in the remaining 9 patients who showed an unsatisfactory response to medication changes. In patients 1 and 13, we detected additional mutations in reverse transcription gene (Table 1) that conferred resistance to efavirenz, thereby accounting for the inadequate response to the previous change of antiretroviral treatment. HIV genotyping did not reveal any resistance-associated mutation in 7 children who had failed 2 changes of treatment regimens, suggesting that limited adherence may account for this observation. Our study demonstrates that HIV genotyping based treatment choices in 17 infected pretreated children led to persistent viral suppression and immunologic reconstitution in 10 children, suggesting that use of this assay improves clinical outcome of antiretroviral-experienced children. A previous study failed to show benefit of HIV resistance testing in a cohort of 18 children. We believe that the limited availability of novel antiretroviral medications and variable adherence to therapeutic regimens may account the different results that are observed in these studies. Drs Badolato and Schumacher contributed equally to this work. Raffaele Badolato, MD, PhD R. Fabian Schumacher, MD Elisabetta Rodella, MD Franco Gargiulo, MD Carlo Torti, MD Luigi D. Notarangelo, MD Marzia Duse, MD Istituto di Medicina Molecolare “Angelo Nocivelli” Clinica Pediatrica Cattedra di Malattie Infettive Laboratorio di Microbiologia University of Brescia Brescia, Italy" @default.
• W2034291261 created "2016-06-24" @default.
• W2034291261 creator A5004535943 @default.
• W2034291261 creator A5018212589 @default.
• W2034291261 creator A5068327775 @default.
• W2034291261 creator A5074373099 @default.
• W2034291261 creator A5078330584 @default.
• W2034291261 creator A5080810066 @default.
• W2034291261 creator A5083864400 @default.
• W2034291261 date "2005-08-01" @default.
• W2034291261 modified "2023-10-16" @default.
• W2034291261 title "Genotyping for Guiding Drug Choice in Human Immunodeficiency Virus-Infected Children Failing Multiple Antiretroviral Treatment Regimens" @default.
• W2034291261 doi "https://doi.org/10.1097/01.inf.0000172910.79381.64" @default.
• W2034291261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16094240" @default.
• W2034291261 hasPublicationYear "2005" @default.
• W2034291261 type Work @default.
• W2034291261 sameAs 2034291261 @default.
• W2034291261 citedByCount "6" @default.
• W2034291261 countsByYear W20342912612013 @default.
• W2034291261 crossrefType "journal-article" @default.
• W2034291261 hasAuthorship W2034291261A5004535943 @default.
• W2034291261 hasAuthorship W2034291261A5018212589 @default.
• W2034291261 hasAuthorship W2034291261A5068327775 @default.
• W2034291261 hasAuthorship W2034291261A5074373099 @default.
• W2034291261 hasAuthorship W2034291261A5078330584 @default.
• W2034291261 hasAuthorship W2034291261A5080810066 @default.
• W2034291261 hasAuthorship W2034291261A5083864400 @default.
• W2034291261 hasBestOaLocation W20342912611 @default.
• W2034291261 hasConcept C104317684 @default.
• W2034291261 hasConcept C126322002 @default.
• W2034291261 hasConcept C135763542 @default.
• W2034291261 hasConcept C142462285 @default.
• W2034291261 hasConcept C156719811 @default.
• W2034291261 hasConcept C159047783 @default.
• W2034291261 hasConcept C203014093 @default.
• W2034291261 hasConcept C2522874641 @default.
• W2034291261 hasConcept C2776452011 @default.
• W2034291261 hasConcept C2777351918 @default.
• W2034291261 hasConcept C2780727368 @default.
• W2034291261 hasConcept C2781143361 @default.
• W2034291261 hasConcept C2781413609 @default.
• W2034291261 hasConcept C2993143319 @default.
• W2034291261 hasConcept C3019165603 @default.
• W2034291261 hasConcept C31467283 @default.
• W2034291261 hasConcept C49105822 @default.
• W2034291261 hasConcept C54355233 @default.
• W2034291261 hasConcept C71924100 @default.
• W2034291261 hasConcept C86803240 @default.
• W2034291261 hasConceptScore W2034291261C104317684 @default.
• W2034291261 hasConceptScore W2034291261C126322002 @default.
• W2034291261 hasConceptScore W2034291261C135763542 @default.
• W2034291261 hasConceptScore W2034291261C142462285 @default.
• W2034291261 hasConceptScore W2034291261C156719811 @default.
• W2034291261 hasConceptScore W2034291261C159047783 @default.
• W2034291261 hasConceptScore W2034291261C203014093 @default.
• W2034291261 hasConceptScore W2034291261C2522874641 @default.
• W2034291261 hasConceptScore W2034291261C2776452011 @default.
• W2034291261 hasConceptScore W2034291261C2777351918 @default.
• W2034291261 hasConceptScore W2034291261C2780727368 @default.
• W2034291261 hasConceptScore W2034291261C2781143361 @default.
• W2034291261 hasConceptScore W2034291261C2781413609 @default.
• W2034291261 hasConceptScore W2034291261C2993143319 @default.
• W2034291261 hasConceptScore W2034291261C3019165603 @default.
• W2034291261 hasConceptScore W2034291261C31467283 @default.
• W2034291261 hasConceptScore W2034291261C49105822 @default.
• W2034291261 hasConceptScore W2034291261C54355233 @default.
• W2034291261 hasConceptScore W2034291261C71924100 @default.
• W2034291261 hasConceptScore W2034291261C86803240 @default.
• W2034291261 hasIssue "8" @default.
• W2034291261 hasLocation W20342912611 @default.
• W2034291261 hasLocation W20342912612 @default.
• W2034291261 hasOpenAccess W2034291261 @default.
• W2034291261 hasPrimaryLocation W20342912611 @default.
• W2034291261 hasRelatedWork W1991061977 @default.
• W2034291261 hasRelatedWork W1992518359 @default.
• W2034291261 hasRelatedWork W2008052978 @default.
• W2034291261 hasRelatedWork W2073234745 @default.
• W2034291261 hasRelatedWork W2095487714 @default.
• W2034291261 hasRelatedWork W2147933179 @default.
• W2034291261 hasRelatedWork W216481071 @default.
• W2034291261 hasRelatedWork W2183166450 @default.
• W2034291261 hasRelatedWork W2402065155 @default.
• W2034291261 hasRelatedWork W4234790260 @default.
• W2034291261 hasVolume "24" @default.
• W2034291261 isParatext "false" @default.
• W2034291261 isRetracted "false" @default.
• W2034291261 magId "2034291261" @default.
• W2034291261 workType "article" @default.